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Abstract 29 
 30 
Objectives: Postoperative atrial fibrillation is the most frequent complication after cardiac surgery, and the 31 
use of statins in preventing them is being extensively studied. The aim of this study was to investigate 32 
whether a pause in the administration of statins affects the occurrence of atrial fibrillation after cardiac 33 
surgery in a prospective randomized and controlled setting. 34 
Methods: A total of 301 patients without chronic atrial fibrillation with prior statin medication scheduled for 35 
elective or urgent cardiac surgery involving the coronary arteries and/or heart valves were prospectively 36 
recruited and randomized for statin re-initiation on either the first (immediate statin group) or the fifth (late 37 
statin group) postoperative day, using the original medication and dosage. The immediate statin group 38 
comprised 146 and the late statin group 155 patients. Except for a somewhat higher rate of males (85% vs. 39 
73%, p=0.016) in the immediate statin group, the baseline characteristics and the distribution of procedures 40 
performed within the groups were comparable. The occurrence of postoperative atrial fibrillation and the 41 
clinical course of the patients were compared between the groups.  42 
Results: The incidence of atrial fibrillation was 46% and the median delay after surgery before the onset of 43 
atrial fibrillation three days in both groups (p=NS). There were no differences observable in the frequency of 44 
the arrhythmia in any subgroup analyses or in other major complications or clinical parameters. No adverse 45 
effects related to early statin administration were detected. 46 
Conclusions: Early re-initiation of statins does not appear to affect the occurrence of postoperative atrial 47 
fibrillation. 48 
 49 
Key words: Atrial fibrillation; Cardiac surgery; Statins 50 
Clinical trial registration: European Union Drug Regulating Authorities Clinical Trials Database 51 
(EudraCT) - 2016-001655-44  52 
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Introduction 53 
 54 
Postoperative atrial fibrillation is the most frequent complication after cardiac surgery, with an occurrence of 55 
approximately 20%–50% [1–3]. The causes and mechanisms of atrial fibrillation remain incompletely 56 
understood but are thought to include surgical trauma, inflammation, adrenergic activation, and oxidative 57 
stress [4–7]. Statins are believed to have anti-inflammatory and anti-oxidative properties, and in recent years 58 
a plethora of literature has emerged investigating the possible effect of statins on the development of 59 
postoperative atrial fibrillation, with initially promising but subsequently contradictory and inconclusive 60 
evidence [8–18].  61 
 62 
The authors hypothesize that statin withdrawal after cardiac surgery might increase the risk for postoperative 63 
atrial fibrillation. The aim of the present study was to investigate whether, in patients with prior statin 64 
medication, a pause in the administration of statins impacts the occurrence of atrial fibrillation following 65 
cardiac surgery in a randomized and controlled setting.  66 
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Materials and Methods 67 
 68 
Ethical statement 69 
The approval of the local Ethics Committee was obtained (approval date 13 June 2016), the Finnish 70 
Medicines Agency was consulted, and the study was registered in the European Union Drug Regulating 71 
Authorities Clinical Trials Database (EudraCT, 2016-001655-44) before initiation and patient enrollment. 72 
The ethical principles laid out in the 1975 Helsinki Declaration were followed. The enrolled patients gave an 73 
informed consent and did not partake in other interventional trials. 74 
 75 
Study design and patients 76 
The study was performed in the Heart Hospital, Tampere University Hospital, Tampere, Finland, a tertiary 77 
referral center, between August 2016 and September 2019. Patients with prior statin medication undergoing 78 
elective or urgent coronary and/or valve surgery were prospectively recruited. The patients with chronic 79 
atrial fibrillation, endocarditis, pacemakers, and/or chronic renal insufficiency requiring dialysis were 80 
excluded, as were those undergoing emergency or complication-related surgery and/or redo-procedures. 81 
Patients on statins that had been initiated during the same hospitalization at least five days before surgery 82 
were included. All recruited patients were randomized into two groups with a 1:1 ratio using a computer-83 
based random number generator. The recruitment of patients as well as their randomization were performed 84 
by the investigators. In the immediate statin group, the statin medication was re-initiated on the first 85 
postoperative day and in the late statin group on the fifth postoperative day. In both groups, the statin that 86 
had been prescribed prior to surgery was used with the original dosage. The study was not blinded. Patients 87 
who were unable to comply with the planned study protocols – for example, because of pharmacological 88 
interactions restricting statin use – were excluded from the trial. 89 
 90 
Peri- and postoperative treatment 91 
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The operations and postoperative care of the patients were otherwise performed according to the clinic 92 
standards. Following surgery, all patients were on continuous and recording electrocardiogram monitoring 93 
throughout the hospitalization. The nursing staff was well-trained in the prompt detection of atrial 94 
fibrillation, and an experienced cardiologist was available on a daily basis for rhythm-related consultations. 95 
Echocardiography was performed at least once on all patients, usually on the third postoperative day. Other 96 
medications, including diuretics, β-blockers, painkillers, antithrombotic agents, and anticoagulants, were at 97 
the attending clinician’s discretion, as were postoperative imaging studies and laboratory examinations. The 98 
clinic’s routine for treating postoperative atrial fibrillation entailed the intravenous administration of 99 
metoprolol (2.5–5 mg), followed by an infusion of amiodarone (300 mg during the first hour and then 900 100 
mg over the next 23 hours), after which electric cardioversion was performed if the arrhythmia persisted. The 101 
routine prophylaxis for thromboembolic complications at the clinic consisted of subcutaneous injections of 102 
enoxaparin 40 mg daily. If atrial fibrillation persisted for more than 24 hours and no severe bleeding issues 103 
were present, the dosage of enoxaparin was increased, and oral anticoagulants, if not already in use, were 104 
considered by the attending surgeon and/or cardiologist. 105 
 106 
Study outcomes and definitions 107 
The primary study outcome was the occurrence of postoperative atrial fibrillation during the in-hospital 108 
period until referral for secondary care or hospital discharge. The patient demographics and medical history, 109 
the type and indication of surgery, as well as clinical parameters, such as perioperative details, the results of 110 
important laboratory parameters, the occurrence of complications, and the length of the hospitalization prior 111 
to hospital discharge or referral for secondary care, were recorded for each patient. The criterion for 112 
postoperative atrial fibrillation was a duration of at least five minutes in the continuous rhythm monitoring. 113 
Perioperative myocardial infarction was defined as the presence of two out of three of the following criteria: 114 
electrocardiographic evidence of myocardial damage, a significant elevation of serum cardiac biomarkers, 115 
and/or the detection of new regional cardiac wall motion abnormalities or loss of viable myocardium in the 116 
echocardiography within 48 hours after surgery. Until and including the 16th of May 2018, the institutional 117 
criterion for a significant rise in cardiac biomarkers was the elevation of creatine kinase isoenzyme MB 118 
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activity to over 75 U/L (≥3 times the upper limit of the reference range), and, thereafter, the elevation of 119 
creatine kinase isoenzyme MB mass to over 50 µg/L (≥10 times the upper limit of the reference range). 120 
Stroke was documented when suggestive neurological symptoms were observed and a corresponding new 121 
lesion in computed tomography was discovered. If a patient required an extended stay in or was readmitted 122 
to the intensive care unit due to severe agitation, confusion, and/or hallucinations, the patient was classified 123 
as having postoperative delirium. The occurrence of postoperative infections, including surgical site 124 
infections, pneumonias, and cannula- and catheter-related infections, was recorded. 125 
 126 
Statistical analyses 127 
The occurrence of postoperative atrial fibrillation was compared between patients in the immediate-statin 128 
and late-statin groups using statistical methods with IBM SPSS version 24 statistical software. The Chi 129 
square and Fisher’s exact test were used to compare categorical data, the Student’s t-test was employed to 130 
compare the means of normally distributed variables, and the Mann-Whitney U-test was applied to compare 131 
the medians of nonparametric scale variables. Statistical significance was set at p<0.05.    132 
 133 
Power analysis 134 
To observe a decrease from 45% to 35% in the occurrence of postoperative atrial fibrillation with α=0.05 and 135 
80% power would require 312 patients in both groups according to the power calculation [19]. An interim 136 
analysis was planned when 300 patients had been recruited to consider the continuation of the study and 137 
further patient recruitment at that time. In the interim analysis with 150 patients in both groups and otherwise 138 
corresponding parameters, the study would have 50% power to detect a similar decrease in the rate of 139 
postoperative atrial fibrillation.   140 
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Results 141 
 142 
The present results represent those of the interim analysis based on which the recruitment of more patients 143 
was discontinued. A total of 303 patients were recruited, two of whom were excluded from the analysis, one 144 
due to accidental recruitment into two interventional studies and the other because of medical interactions 145 
limiting the planned statin use. The demographic information and medical history of the final study 146 
population are shown in Table 1. The groups were otherwise comparable, but there was a somewhat higher 147 
proportion of males in the immediate statin group. The statin medications prescribed for the patients are 148 
summarized in Table 2. For a total of 22% of the patients, the medication was initiated during the 149 
hospitalization when the surgery was performed, with no statistically significant differences between the 150 
study groups. The types of surgery performed as well as the perioperative details and major outcomes of the 151 
study patients are depicted in Table 3.  152 
 153 
A total of 46% (95% CI 40-52%) of the patients had a postoperative episode of atrial fibrillation and 28% 154 
(95% CI 23%–33%) more than one episode. Figure 1 illustrates the main results of the study, showing no 155 
significant differences in the main study outcome – the occurrence of postoperative atrial fibrillation – 156 
between the groups. Most of the procedures were performed for coronary disease, followed by single-valve 157 
surgeries, which were mostly for aortic valves, and combination procedures. There were no statistically 158 
significant differences in the occurrence or the recurrence rate of postoperative atrial fibrillation between the 159 
study groups, nor was there an observable trend towards a lower incidence in the immediate statin group. 160 
Moreover, no significant differences were seen between different statins. Of the patients previously 161 
diagnosed with paroxysmal atrial fibrillation, 73% also had an episode postoperatively, in comparison to the 162 
corresponding 43% among other patients, p=0.005, but there were no statistically significant differences in 163 
the said proportions between the study groups. In patients for whom statins had been initiated during the 164 
same hospitalization, the rates of postoperative atrial fibrillation and recurring atrial fibrillation were 48% 165 
and 29%, respectively, with no statistically significant differences between the study groups. The median 166 
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delay between surgery and the development of postoperative atrial fibrillation was three days in both groups, 167 
p=0.26. The occurrence of other major adverse outcomes was also similar between the groups. The mean 168 
peak C-reactive protein concentration was slightly lower in the immediate statin group when compared to the 169 
late statin group. The prevalence of sinus rhythm at referral for secondary care or hospital discharge was 170 
97%, with no differences between the groups.  171 
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Discussion 172 
 173 
Postoperative atrial fibrillation remains a challenge in the care of cardiac surgical patients, and its 174 
significance may even be increasing as contemporary surgical programs face older, more morbid patients, 175 
with higher rates of extensive as well as urgent and emergency procedures performed. Though frequently 176 
considered a minor complication, atrial fibrillation is also associated with an inferior prognosis and an 177 
increased risk of stroke in long-term follow-up, even if its prevention may not mitigate these risks as clearly 178 
[20–22]. Statins have demonstrated clear beneficial effects in several patient subgroups with cardiovascular 179 
diseases and are also currently being studied in the prevention of atrial arrhythmias following cardiac 180 
surgery. The postulated mechanisms of action are the pleiotropic effects of statins, which are still 181 
incompletely understood [23]. The present study was initiated to ascertain whether statin withdrawal affects 182 
the occurrence of atrial fibrillation after cardiac surgery but based on the results of the interim analysis in 183 
which no apparent effect or trend was observable, the study was discontinued. Furthermore, no adverse 184 
effects related to early statin reinstitution, nor changes in the creatine kinase levels, were detected in this 185 
study. 186 
 187 
The rationale for the present study was the relatively high occurrence of postoperative atrial fibrillation at the 188 
study center, which was also observable in the present study [1]. Earlier, the institutional protocol for 189 
patients on prescribed statins prior to surgery was to reinstitute them on the fifth postoperative day, and the 190 
discourse regarding the impact that statins might have on the development of atrial arrhythmias after major 191 
procedures such as surgery led to the present hypothesis. Other possible explanations for the high incidence 192 
include changes in the patient material that is being referred for surgery – and in the respective prevalence of 193 
consequential comorbidities – and/or a better detection rate with the adoption of continuous rhythm 194 
monitoring, when compared to preceding studies performed in the 1990s and 2000s. Despite the high 195 
occurrence of atrial fibrillation episodes in the present material, virtually all patients were in sinus rhythm at 196 
the end of the treatment period, implying efficient measures in treating the episodes. 197 
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 198 
While the prevention of postoperative atrial fibrillation is relevant for virtually all patients undergoing 199 
cardiac surgery as well as other major procedures, the authors recognize that some preventive methods might 200 
apply to some but not all patient subgroups. For example, the study included patients both with and without 201 
paroxysmal atrial fibrillation. Previous atrial fibrillation is an established risk factor for postoperative atrial 202 
arrhythmia episodes, and these patients may represent a cohort in which preventive measures have a different 203 
magnitude of effect. In the subgroup analyses performed, however, there was no observable trend for a 204 
benefit in any patient subgroup. The only statistically significant difference between the groups was seen in 205 
the C-reactive protein concentration, but in the absence of an association with clinical events, its significance 206 
remains unclear and the result may have been coincidental. The authors speculate that, even if statins would 207 
be theoretically beneficial in the early postoperative phase, their absorption from the gastrointestinal tract 208 
might be significantly impaired at this stage, thus diminishing their possible effect. A similar finding has 209 
been reported regarding β-blockers, for example [24]. Furthermore, while the plasma half-life of statins 210 
ranges from a few hours to approximately one day, the duration of their pleiotropic effects is not known [25]. 211 
Should they last for several days, they could diminish the effects of a short statin pause and contribute to the 212 
negative results of the present study. As to whether statins might prevent postoperative atrial fibrillation 213 
remains uncertain, and caution is warranted in postulating possible mechanisms of action. 214 
 215 
Though procedures involving the atrioventricular valves or the thoracic aorta as well as combination 216 
procedures are associated with a clear risk of atrial fibrillation, the study did not include many such patients, 217 
for two reasons. Firstly, these procedures, with the exception of those concerning the mitral valve, are not as 218 
frequent as others, such as coronary bypass surgery. Secondly, it became apparent that many of these patients 219 
were either young and otherwise healthy and therefore not receiving statins, or they had already developed 220 
chronic atrial fibrillation, thus excluding them from the study. It would have also been interesting to compare 221 
the rates of postoperative atrial fibrillation to an otherwise similar group of patients with no concurrent statin 222 
treatment. However, virtually every patient who was referred for surgery with an indication for statins was 223 
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already on prescribed statins, making it impossible to recruit such patients in sufficient numbers. All in all, 224 
these results are more representative of patients in need of coronary or aortic valve procedures.  225 
 226 
The decision to recontinue the statins that were already in use with the original dose may be criticized 227 
because it allowed for heterogeneity in the study intervention, and it would have been clearer if a single class 228 
and dosage of statins had been adopted. However, it is the opinion of the authors that, as most patients are 229 
already on statins when referred for surgery, it may not be prudent to overlook the decisions of the primary 230 
care physicians and the experiences of the patients, since it is not uncommon for patients to tolerate some but 231 
not all statins [26]. The approach used here would have been well-suited for implementation in most 232 
programs in the developed countries, but others might be more feasible in scenarios in which statin-naïve 233 
patients are treated. 234 
 235 
Study limitations 236 
The main weaknesses of the present study include its single-center setting and the heterogeneity of the study 237 
material and intervention. The decision to include patients with paroxysmal atrial fibrillation may be faulted, 238 
but the authors argue that these patients are increasingly numerous and also represent those who are at a high 239 
risk of postoperative arrhythmias and in whom the benefits of prophylaxis, i.e. decreased morbidity and 240 
reduced need for therapeutic measures, may be relevant. The institutional criteria for perioperative 241 
myocardial infarction differed from what has been suggested in clinical guidelines, and the rates may thus 242 
not be directly compared to other studies. The study may not have sufficient statistical power to completely 243 
refute the study hypothesis, but should there be an effect, it would appear extremely unlikely, minimal, and 244 
not demonstrable even if the present study would have been completed. It is important to remember, that 245 
while this study does not disprove a possible preventive role of statins in postoperative atrial fibrillation, it 246 
would appear that whether or not they are administered postoperatively does not clearly affect the occurrence 247 
of the arrhythmia. It is also possible that the effect of statins is more pronounced initially, as the reduction in 248 
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postoperative atrial fibrillation has been mostly observed in statin-naïve patients with a short duration of 249 
statin therapy prior to surgery.  250 
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Conclusion 251 
 252 
The authors report that, in patients receiving statins prior to cardiac surgery, whether or not statins were 253 
given immediately after surgery had no apparent effect on the occurrence of postoperative atrial fibrillation 254 
in this randomized controlled study. 255 
 256 
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Figure legends 260 
 261 
Figure 1. The occurrence and recurrence of postoperative atrial fibrillation in patients treated with 262 
immediate and late statin protocols. There were no statistically significant differences between the groups or 263 
within subgroups according to the statin treatment protocol    264 
265 
.  266 
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Table 1. The baseline characteristics of included patients. 267 
 
Immediate statin Late statin p 
Number of patients 146 155 
 
Male (%) 85% 73% 0.016 
Mean age (years) 69 (8.5) 67 (7.9) 0.08 
Mean body mass index (kg/m2) 28 (4.4) 29 (4.7) 0.24 
Diabetes 36% 28% 0.17 
Coronary disease 79% 86% 0.13 
Hypertension 75% 74% 0.90 
Active smoking 8.9% 12% 0.46 
Former smoking 27% 27% 0.90 
Chronic pulmonary disease 10% 9.7% 0.86 
Peripheral artery disease 11% 5.8% 0.14 
Paroxysmal atrial fibrillation 9.6% 10% 0.60 
Family history of heart diseases 40% 37% 0.54 
Preoperative glomerular filtration rate (ml/min) 82 (20) 84 (23) 0.46 
Preoperative hemoglobin (g/L) 139 (14) 139 (16) 0.99 
Urgent surgery 29% 25% 0.52 
NYHA 3–4 (%) 51% 52% 0.82 
Mean Euroscore-II 2.2% 1.9% 0.62 
Mean preoperative LVEF 60% 56% 0.21 
Mean left atrial size (mm) 40 (7.5) 40 (6.2) 0.68 
Results are presented as means and standard deviations for numeric variables and percentages for categorical 268 
variables.  269 
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Table 2. The distribution of the classes of statins as well as the proportions of applied dosages within each 270 
class that were in use among the recruited patients. There were no statistically significant differences 271 
between the groups. 272 
Statin class and dosage Immediate statin 
(n=146) 
Late statin 
(n=155) 
Atorvastatin 47% 52% 
 10 mg 19% 6.2% 
 20 mg 29% 38% 
 40 mg 48% 50% 
 80 mg 4.3% 6.2% 
Simvastatin 32% 26% 
 10 mg 6.5% 7.5% 
 20 mg 22% 35% 
 40 mg 67% 58% 
 60 mg 0% 2.2% 
 80 mg 0% 2.2% 
Rosuvastatin 17% 16% 
 5 mg 20% 13% 
 10 mg 44% 50% 
 20 mg 32% 33% 
 40 mg 4.0% 4.2% 
Pravastatin 2.1% 3.9% 
 20 mg 100% 50% 
 40 mg 0% 50% 
Fluvastatin 2.1% 2.6% 
 20 mg 33% 25% 
 80 mg 67% 75% 
18 
 
Lovastatin 0% 0.6% 
 40 mg 0% 100% 
  273 
19 
 
Table 3. The types of procedures performed, perioperative details, and the major outcomes in study patients. 274 
 Immediate statin 
(n=146) 
Late statin 
(n=155) 
p 
Coronary surgery 70% 65% 0.33 
Single-valve or aortic root surgery1 21% 21% 0.99 
Coronary surgery with valve or aortic procedures2 8.9% 14% 0.21 
Mean X-clamp time (min) 107 (41) 104 (41) 0.52 
Mean on-pump time (min) 132 (49) 129 (52) 0.60 
Mean weight gain3 (kg) 6.4 (3.0) 6.4 (2.9) 0.90 
Median peak creatine kinase (U/L)3 511 (382) 484 (415) 0.44 
Mean peak C-reactive protein concentration (mg/L) 3 160 (60) 175 (77) 0.049 
Mean maximal hemoglobin decrease (g/L)3 41 (19) 41 (15) 0.79 
Perioperative myocardial infarction4 4.3% 4.1% 0.99 
Reoperation for bleeding 6.2% 3.9% 0.43 
Postoperative infections 4.1% 3.2% 0.77 
Stroke 2.7% 0.6% 0.20 
Delirium5 6.2% 3.2% 0.28 
Median length of hospital stay (days) 5 (2) 5 (3) 0.11 
In-hospital mortality 0% 1.4% 0.23 
Results are presented as means and standard deviations or medians and interquartile ranges for numeric 275 
variables and as percentages for categorical variables. 276 
1Includes 52 procedures involving the aortic valve, eight involving the aortic valve and root, one involving 277 
the aortic valve and ascending aorta, two involving the mitral valve, and one involving the tricuspid valve.  278 
2Includes 26 procedures involving the aortic valve, five involving the aortic valve and root, one involving the 279 
mitral valve, one involving the tricuspid valve, and two involving the ascending aorta in addition to coronary 280 
bypasses. 281 
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3Within seven days after surgery. 282 
4Diagnostic criteria include two out of three of the following: electrocardiographic changes indicative of 283 
ischemia, a significant elevation in cardiac biomarkers (creatine kinase MB activity exceeding 75 U/L [≥3x 284 
the upper limit of the reference range] until and including the 16th of May 2018, or creatine kinase isoenzyme 285 
MB mass over 50 µg/L [≥10x the upper limit of the reference range] thereafter), and/or the presence of 286 
cardiac wall motion abnormalities or loss of viable myocardium in echocardiography within 48 hours after 287 
surgery. 288 
5Requiring extended stay in or readmittance to the intensive care unit.  289 
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